Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H27N3O6 |
| Molecular Weight | 381.4235 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1)C(O)=O
InChI
InChIKey=MQGGXGKQSVEQHR-KKUMJFAQSA-N
InChI=1S/C18H27N3O6/c1-10(2)7-14(18(26)27)20-17(25)15(9-22)21-16(24)13(19)8-11-3-5-12(23)6-4-11/h3-6,10,13-15,22-23H,7-9,19H2,1-2H3,(H,20,25)(H,21,24)(H,26,27)/t13-,14-,15-/m0/s1
| Molecular Formula | C18H27N3O6 |
| Molecular Weight | 381.4235 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Tyroserleutide (YSL) is a tripeptide treatment being developed by Shenzhen Kangzhe Pharmaceutical Co Ltd, a subsidary of China Medical System Holdings (CMS), for the treatment of liver cancer. It is initially separated and purified from the hydrolyzates of pig’s spleen, but now can be obtained by chemical synthesis, its chemical name is L-tyrosine-L-serine-L-leucine. Tyroserleutide is an active, low-molecular-weight polypeptide, comprised of three amino acids, that has shown antitumor effects on human hepatocarcinoma BEL-7402 in vitro and in vivo. Tyroserleutide has various advantages over the other bioactive peptides such as its low molecular weight, simple construction, nonimmunogenicity, specificity, few side effects, and ease of synthesis. Tyroserleutide is in Phase-III clinical trials for the treatment of liver cancer.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| The effect of tripeptide tyroserleutide (YSL) on animal models of hepatocarcinoma. | 2006 Jun |
|
| Effects of Tyroserleutide on phosphatidylinositol 3'-kinase/AKT pathway in human hepatocellular carcinoma cell. | 2014 Feb |
|
| Therapeutic effects of tyroserleutide on lung metastasis of human hepatocellular carcinoma SK-HEP-1 and its mechanism affecting ICAM-1 and MMP-2 and -9. | 2018 |
Sample Use Guides
Hepatocellular carcinoma: continuous administration of Tyroserleutide (YSL) by a portable infusion pump; forty patients (12 in stage 1, 28 in stage 2, total 10 treated in each dose cohort) were treated with Tyroserleutide 6, 12, 18, or 24 mg/day lasting for 5 days.
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 06:43:37 GMT 2023
by
admin
on
Sat Dec 16 06:43:37 GMT 2023
|
| Record UNII |
L9TIM50J8N
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
190604
Created by
admin on Sat Dec 16 06:43:37 GMT 2023 , Edited by admin on Sat Dec 16 06:43:37 GMT 2023
|
||
|
NCI_THESAURUS |
C274
Created by
admin on Sat Dec 16 06:43:37 GMT 2023 , Edited by admin on Sat Dec 16 06:43:37 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
L9TIM50J8N
Created by
admin on Sat Dec 16 06:43:37 GMT 2023 , Edited by admin on Sat Dec 16 06:43:37 GMT 2023
|
PRIMARY | |||
|
138168-48-6
Created by
admin on Sat Dec 16 06:43:37 GMT 2023 , Edited by admin on Sat Dec 16 06:43:37 GMT 2023
|
PRIMARY | |||
|
10045387
Created by
admin on Sat Dec 16 06:43:37 GMT 2023 , Edited by admin on Sat Dec 16 06:43:37 GMT 2023
|
PRIMARY | |||
|
C77856
Created by
admin on Sat Dec 16 06:43:37 GMT 2023 , Edited by admin on Sat Dec 16 06:43:37 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
